SCHEMBL4389864

SCHEMBL4389864

OCCC(Br)Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 0.45
SLC6A2 P23975 2/20 0.45
TAAR1 Q96RJ0 2/20 0.45
MAOA P21397 1/20 0.45
SLC6A4 P31645 1/20 0.45
SLC6A3 Q01959 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
CYP2A6 P11509 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA1 P30542 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
CYP1A2 P05177 1/20 0.43
EPHX1 P07099 1/20 0.43
TSHR P16473 2/20 0.42
ALPI P09923 1/20 0.41
PKM P14618 1/20 0.41
PTGS1 P23219 1/20 0.41
XIAP P98170 1/20 0.41
SLC7A5 Q01650 1/20 0.41
CPA3 P15088 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1552921 0.82 TRPA1 (0.54) TRPA1SLC6A2TAAR1MAOASLC6A4
SCHEMBL12708159 0.82 TRPA1 (0.54) TRPA1SLC6A2TAAR1MAOASLC6A4
SCHEMBL7252952 0.81 EPHX1 (0.55) TRPA1SLC6A2TAAR1MAOASLC6A4
SCHEMBL6682088 0.80 TDP1 (0.46) TRPA1SLC6A2TAAR1MAOASLC6A4
SCHEMBL9456004 0.80 TDP1 (0.46) SLC6A2TAAR1MAOASLC6A4SLC6A3
Hydrogen Sulfide SCHEMBL9623454 0.79 EPHX1 (0.52) TRPA1SLC6A2TAAR1MAOASLC6A4
SCHEMBL29828349 0.78 EPHX1 (0.48) SLC6A2TAAR1MAOASLC6A4SLC6A3
SCHEMBL8746113 0.78 SIGMAR1 (0.46) TRPA1SLC6A2TAAR1MAOASLC6A4
SCHEMBL1114633 0.78 CPA3 (0.62) SLC6A3CYP1A2TSHRALPIPKM
SCHEMBL9441158 0.77 CYP1A2 (0.52) TRPA1SLC6A2TAAR1MAOASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4121438-A2 NEUROACTIVE STEROIDS AND THEIR METHODS OF USE Sage Therapeutics, Inc. (US) 2023-01-25 EP disclosed
WO-2021188778-A2 NEUROACTIVE STEROIDS AND THEIR METHODS OF USE SAGE THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed
US-20090181948-A1 DIAMINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-07-16 US disclosed
EP-1847530-A1 DIAMINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed
EP-0863875-B1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY HOFFMANN LA ROCHE (CH) 2003-06-04 EP disclosed
US-6420574-B1 2002-07-16 US disclosed
US-6420574-B2 REACTING 1-(4-FLUOROPHENYL)-1,3-DIHYDROISOBENZOFURAN-5-CARBONITRILE WITH SUBSTITUTED ALKYL HALIDE/SULFONATE; CHEMICAL INTERMEDIATE CONVERTED TO AMINE; ANTIDEPRESSANT; AVOIDS BY-PRODUCT FORMATION H. LUNDBECK A/S (DK) 2002-07-16 US disclosed
US-20010027256-A1 Method for the preparation of citalopram H. LUNDBECK A/S (DK) 2001-10-04 US disclosed
EP-0863875-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1998-09-16 EP disclosed
WO-1997009311-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1997-03-13 WO disclosed
CN-1076690-A SULFONAMIDOCARBOXAMIDES HOFFMANN LA ROCHE (CH) 1993-09-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181948-A1 DIAMINE DERIVATIVE ARG1, PRMT5, PRMT1 TRPA1 4666/4885SLC6A2 3400/4885TAAR1 1445/4885
US-20010027256-A1 Method for the preparation of citalopram CRHR1, CRHR2, MC3R TRPA1 4632/4885SLC6A2 157/4885TAAR1 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.